Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia

A 55-year-old woman with central centrifugal cicatricial alopecia (CCCA) and traction alopecia (TA) showed significant hair regrowth after 6 months of treatment with topical ruxolitinib, a JAK1/2 inhibitor, combined with oral minoxidil. This case suggests that topical JAK inhibitors could be a promising treatment for scarring alopecias like CCCA and TA, particularly when traditional treatments are ineffective. The study indicates the JAK/STAT pathway's significant role in CCCA's pathophysiology and proposes that topical JAK inhibitors might be a safer alternative to oral treatments, which carry immunosuppression risks. Further research is necessary to validate these findings and assess the effectiveness of topical JAK inhibitors for scarring alopecias.